We expect 2025 to bring ph2 head-and-neck cancer data and data from certain brain cancers, as well as finalisation of the pivotal trial design of FG001. We have pushed back our base-case launch assumption from 2026 to 2028, although the major inflection points seem likelier to be post-2025 events to us. Cash and facilities should be sufficient to fund operations into Q4/25. NPV-based valuation range mid-point SEK 153 (181) per share.
LÄS MER
